Chester County News and Community Website
PHILADELPHIA, PA — Virion Therapeutics, LLC said it presented data at the 33rd Conference on Retroviruses and Opportunistic Infections in Denver showing that a single intramuscular dose of its investigational …
Virion Reports VRON-0200 Data in Chronic Hepatitis B Study Read More
MALVERN, PA — NexEos Bio Vision Health said that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to begin a Phase II/III clinical trial of …
NexEos Bio Vision Health Wins FDA Clearance for NTX-1024 Trial Read More
WASHINGTON, D.C. — The Food and Drug Administration has released draft guidance outlining a new pathway to approve highly individualized treatments for ultra-rare diseases and has granted expedited approval to …
FDA Unveils Ultra-Rare Therapy Path, Fast-Tracks Lung Drug Read More
NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) announced completion of a 90-patient Phase 2 study evaluating its investigational COVID-19 treatment ratutrelvir against PAXLOVID® and provided an update on development …
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update Read More
DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial showing a second unconfirmed partial response in a patient with advanced …
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial Read More
WILMINGTON, DE — AstraZeneca (NYSE: AZN) said full results from the Phase III KALOS and LOGOS trials, published in The Lancet Respiratory Medicine, showed its triple-combination inhaler BREZTRI Aerosphere significantly …
AstraZeneca Reports Phase III Results for BREZTRI in Asthma Read More
HORSHAM, PA — STRATA Skin Sciences Inc. (Nasdaq: SSKN) highlighted a February 2026 systematic review and meta-analysis that found the 308 nm excimer laser to be clinically effective in treating …
STRATA Cites Study Supporting 308 Nm Laser for Psoriasis Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has recommended continuation of its ongoing Phase 3 clinical trial of buntanetap in …
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate a Phase 2b dose-optimization trial …
Medicus Pharma Receives FDA Clearance to Begin Phase 2b Teverelix Study Read More
PHILADELPHIA, PA — Aro Biotherapeutics reported interim data from a Phase 1b study of ABX1100, an investigational therapy for late-onset Pompe disease, showing the drug was generally well tolerated and …
Experimental Pompe Therapy Shows Early Promise in Trial Read More